hVIVO plc (AIM & Euronext: HVO), a rapidly expanding specialist contract research organisation (CRO) renowned for its expertise in human challenge clinical trials for infectious and respiratory diseases, has announced its latest engagement in a significant Phase 2b field study. The study will assess an influenza drug candidate, marking a milestone as hVIVO’s largest field […]
In a significant stride toward revolutionizing drug discovery and development, Seoul-based biotech firm Oncocross announced on May 22nd a renewed joint research agreement with JW Pharmaceutical. This collaboration aims to leverage artificial intelligence to accelerate the development of new drugs, particularly in the fields of anticancer and regenerative medicine. Leveraging AI for Faster, More Efficient […]
Bexion Pharmaceuticals has launched part 3 of its phase 1 clinical trial for BXQ-350, an investigational cancer treatment aimed at advancing the fight against solid tumors. This milestone marks a significant step forward for the US-based pharma company, which has been diligently working to explore the therapeutic potential of BXQ-350. The phase 1 trial, still […]